Trial Profile

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Artesunate (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Remdesivir (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Acronyms SOLIDARITY; Solidarity PLUS

Most Recent Events

20 Jun 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
11 May 2023 The study has been suspended in Latvia and Portugal, according to European Clinical Trials Database record.
15 Sep 2022 Results published in the Gilead Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com